Transplanters drive CARs to the clinic by brewing ICE-T: the Moffitt roadmap

Abstract

Abstract Recent single institution clinical trial successes with anti-CD19 Chimeric Antigen Receptor (CAR) T cell therapy for B cell malignancies attracted significant attention from industry. Our center sought to rapidly and safely bring industry sponsored pivotal trials to our patients and to prepare for additional cell therapy trials in solid and liquid tumors from both industry and our own investigators. We implemented a collaborative cross departmental program to provide clinical care and trial coordination for immune cell therapies. The Moffitt Immune Cell Therapy (ICE-T) program oversees and administers not only CAR T cell therapy for hematologic malignancies, but TIL and TCR therapy for solid tumor patients. Disease specific experts maintain oversight as principal investigators of these key trials yet the coordination and clinical care is centralized to leverage the expertise and infrastructure of our already robust Blood and Marrow Transplantation program.

Keywords

• Chimeric antigen receptor (CAR) therapy
• Cytotoxic T lymphocytes
• Cell therapy
• T cell receptor (TCR) therapy
• Tumor infiltrating lymphocyte (TIL) therapy
• Cytokine release syndrome